Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer

被引：43

作者：

Falchook, Gerald S. ^{[1
]}

Ordonez, Nelson G. ^{[1
]}

Bastida, Christel C. ^{[1
]}

Stephens, Philip J. ^{[2
]}

Miller, Vincent A. ^{[2
]}

Gaido, Lindsay ^{[1
]}

Jackson, Tiffiny ^{[1
]}

Karp, Daniel D. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Fdn Med, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

PHASE-III TRIAL; DOUBLE-BLIND; PLUS DOCETAXEL; PROTOONCOGENE; NEOPLASIA; RECEPTOR; GENE; ACTIVATION; EXPRESSION; DIAGNOSIS;

D O I：

10.1200/JCO.2013.50.5016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E141 / E144

页数：4

共 28 条

[1] RET and NTRK1 proto-oncogenes in human diseases [J].

Albert, L ;

Carniti, C ;

Miranda, C ;

Roccato, E ;

Pierotti, MA .

JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (02) :168-186

[2] A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer [J].

Blackhall, Fiona H. ;

O'Brien, Mary ;

Schmid, Peter ;

Nicolson, Marianne ;

Taylor, Paul ;

Milenkova, Tsveta ;

Kennedy, Sarah J. ;

Thatcher, Nick .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) :1285-1288

[3]

Carlomagno F, 2002, CANCER RES, V62, P7284

[4] Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer [J].

Dawson, DM ;

Lawrence, EG ;

MacLennan, GT ;

Amini, SB ;

Kung, HJ ;

Robinson, D ;

Resnick, MI ;

Kursh, ED ;

Pretlow, TP ;

Pretlow, TG .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (07) :519-523

[5] An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer [J].

de Boer, R. ;

Humblet, Y. ;

Wolf, J. ;

Nogova, L. ;

Ruffert, K. ;

Milenkova, T. ;

Smith, R. ;

Godwood, A. ;

Vansteenkiste, J. .

ANNALS OF ONCOLOGY, 2009, 20 (03) :486-491

[6] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial [J].

de Boer, Richard H. ;

Arrieta, Oscar ;

Yang, Chih-Hsin ;

Gottfried, Maya ;

Chan, Valorie ;

Raats, Johann ;

de Marinis, Filippo ;

Abratt, Raymond P. ;

Wolf, Juergen ;

Blackhall, Fiona H. ;

Langmuir, Peter ;

Milenkova, Tsveta ;

Read, Jessica ;

Vansteenkiste, Johan F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :1067-1074

[7] Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas [J].

Drilon, Alexander ;

Wang, Lu ;

Hasanovic, Adnan ;

Suehara, Yoshiyuki ;

Lipson, Doron ;

Stephens, Phil ;

Ross, Jeffrey ;

Miller, Vincent ;

Ginsberg, Michelle ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc ;

Rizvi, Naiyer .

CANCER DISCOVERY, 2013, 3 (06) :630-635

[8] RET proto-oncogene in the development of human cancer [J].

Eng, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :380-393

[9] Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer [J].

Hanrahan, Emer O. ;

Lin, Heather Y. ;

Kim, Edward S. ;

Yan, Shaoyu ;

Du, Danny Z. ;

McKee, Kathryn S. ;

Tran, Hai T. ;

Lee, J. Jack ;

Ryan, Anderson J. ;

Langmuir, Peter ;

Johnson, Bruce E. ;

Heymach, John V. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :193-201

[10] Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer [J].

Hanrahan, Emer O. ;

Ryan, Anderson J. ;

Mann, Helen ;

Kennedy, Sarah J. ;

Langmuir, Peter ;

Natale, Ronald B. ;

Herbst, Roy S. ;

Johnson, Bruce E. ;

Heymach, John V. .

CLINICAL CANCER RESEARCH, 2009, 15 (10) :3600-3609

← 1 2 3 →